| | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 游资净占比 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-10-27 | 4.89 0.41% | 109.62万 | 1.65% | 109.89万 | 1.66% | -219.50万 | -3.31% | | 2025-10-24 | 4.87 -0.41% | 389.32万 | 8.11% | -66.54万 | -1.39% | -322.79万 | -6.72% | | 2025-10-23 | 4.89 0.20% | 170.77万 | 3.48% | -277.80万 | -5.65% | 107.03万 | 2.18% | | 2025-10-22 | 4.88 0.41% | 443.26万 | 7.37% | -412.30万 | -6.86% | -30.96万 | -0.52% | | 2025-10-21 | 4.86 0.62% | -226.12万 | -3.83% | 260.42万 | 4.42% ...

证券代码：000516 证券简称：国际医学 公告编号：2025-046 二、控股股东及其一致行动人股份累计质押的基本情况 截至公告披露日，世纪新元及其一致行动人所持质押股份情况如下： | | | | 本次质 | 本次质 | | | 已质押股份 | | 未质押股份 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 押前质 | 押后质 | 占其 | 占公 | 情况 | | 情况 | | | 股东 | 持股数量 | 持股 | | | 所持 | 司总 | 已质押股 | 占已 | 未质押股 | 占未 | | | | | 押股份 | 押股份 | | | | | | | | 名称 | （股） | 比例 | | | 股份 | 股本 | 份限售和 | 质押 | 份限售和 | 质押 | | | | | 数量 | 数量 | 比例 | 比例 | | | | | | | | | （股） | （股） | | | 冻结数量 | 股份 | 冻结数量 | 股份 | | | | | | | | | （股） | 比例 | （股） | 比例 ...

Core Insights - The third China-Korea (Jinan) Health Industry New Technology Enterprise Exchange event was held to deepen cooperation in the health sector between China and South Korea [1][10] - Several collaborative projects were signed, including new drug development for muscle-wasting metabolic diseases and innovative dental implant production [3][10] Group 1: Event Overview - The event was organized by Jinan International Medical Center, Shandong First Medical University, and the Korea Small and Medium Enterprises Agency [1] - The event showcased significant achievements in China-Korea health industry cooperation [3] Group 2: Collaborative Projects - New projects include the establishment of a production base for innovative dental implants and the production of new materials for urinary catheters [3] - Mitos and Dedawei companies shared successful experiences of collaboration, enhancing confidence among Korean companies to invest in China [5] Group 3: Technology Showcase - Ten Korean companies presented advanced technologies in areas such as cell and gene therapy, innovative dental implants, and smart medical devices [7] - The presentations highlighted the innovative vitality and potential of the health industry, laying a foundation for further cooperation [7] Group 4: Financial Collaboration - A China-Korea enterprise and financial institution matchmaking session was held, involving multiple investment institutions from both countries [8] - Financial institutions played a crucial role in facilitating cooperation by providing a stable and efficient financial platform [8] Group 5: Future Outlook - The successful hosting of the event is expected to inject new vitality and strong momentum into the cooperation between the two countries in the health industry [10] - Both countries aim to continue working together to create a promising future for the health industry [10]

Core Viewpoint - The company is focusing on enhancing operational efficiency and service quality in response to industry policy changes, particularly in medical insurance payment reforms [1] Group 1: Company Strategy - The company plans to strengthen cost control and improve operational efficiency while expanding service scale in a structured manner [1] - A differentiated strategy will be employed to build competitive advantages and enhance service value [1] - The company aims to optimize its capital structure through diversified financing channels to improve debt structure and reduce financial costs [1] Group 2: Financial Performance - As of October 21, 2025, the company's stock closed at 4.86 yuan, with a 0.62% increase and a trading volume of 12.17 million shares, amounting to a transaction value of 58.96 million yuan [1] - The company's current asset-liability ratio is considered reasonable, and it has sufficient comprehensive credit exposure [1] Group 3: Project Updates - The proton therapy center at Xi'an International Medical Center Hospital, the first of its kind in Northwest China, is under construction and will commence operations upon obtaining necessary administrative approvals [1] Group 4: Market Sentiment - On October 21, the main funds experienced a net outflow of 2.26 million yuan, accounting for 3.84% of the total transaction value [2] - Retail investors saw a net outflow of 0.34 million yuan, representing 0.58% of the total transaction value [2]

Core Viewpoint - International Medical (000516) has shown a mixed performance in recent trading sessions, with fluctuations in stock price and varying capital flows, indicating potential volatility in investor sentiment [1][2]. Financial Performance - As of the latest report, International Medical's total market value is 10.881 billion yuan, with a net asset value of 3.21 billion yuan [3]. - The company reported a net profit of -165 million yuan, reflecting a year-on-year increase of 4.98%, while its main revenue decreased by 15.95% to 2.034 billion yuan [3]. - The gross profit margin stands at 7.8%, significantly lower than the industry average of 35.92% [3]. Capital Flow Analysis - On October 21, 2025, the stock price closed at 4.86 yuan, with a slight increase of 0.62%. The main capital flow showed a net outflow of 2.2612 million yuan, accounting for 3.83% of the total transaction volume [1][2]. - Over the past five days, the stock has experienced varying capital flows, with notable net inflows from speculative funds on certain days, while main capital has seen consistent outflows [2]. Industry Comparison - In comparison to the healthcare services industry, International Medical ranks low in several key metrics, including net profit and return on equity (ROE), with a ROE of -4.6% compared to the industry average of 2.19% [3]. - The company's price-to-earnings ratio (P/E) is -32.98, indicating a lack of profitability relative to its peers [3]. Analyst Ratings - Recently, two institutions have provided ratings for the stock, with one buy rating and one hold rating, suggesting a cautious outlook among analysts [4].

证券日报网讯国际医学10月21日在互动平台回答投资者提问时表示，国际化战略一直是国际医学发展规 划重要方向之一。国际医学的国际化不仅仅体现在业内领先的硬件设备，更是在医院资质、诊疗标准、 诊疗模式、服务流程、人才培养、科研创新和学术交流等方面的国际化，最终使患者在"家门口"就能享 受到国际化的优质医疗服务。围绕既定战略方向和发展需求，国际医学在挖掘全球优质医疗资源、拓展 国际合作方面进行了诸多探索与尝试，积极参与国际行业会议，组织海内外调研，并与欧洲、美洲、亚 洲及港澳台地区的知名医疗机构、高校、科技公司等进行了广泛的联络与交流。未来，国际医学将在现 有国际化布局基础上，打造卓越中心和优势专科；积极推动医教研的深度融合、协同发展；加强团队建 设和国际人才引进；提升企业精益管理水平。 （文章来源：证券日报） ...

Core Viewpoint - International Medical (000516) experienced a decline in stock price, closing at 4.91 yuan on October 16, 2025, with a drop of 1.21% and a trading volume of 107,800 hands, resulting in a transaction amount of 53.16 million yuan [1] Financial Performance - The company reported a total revenue of 2.034 billion yuan for the first half of 2025, a year-on-year decrease of 15.95% [3] - The net profit attributable to shareholders was -165 million yuan, an increase of 4.98% year-on-year [3] - The net profit after deducting non-recurring items was -189 million yuan, a decrease of 36.09% year-on-year [3] - In Q2 2025, the company’s revenue was 1.037 billion yuan, down 16.86% year-on-year, while the net profit attributable to shareholders was -58.61 million yuan, up 14.68% year-on-year [3] Market Position and Ratios - The total market capitalization of International Medical is 10.993 billion yuan, ranking 12th in the medical services industry [3] - The company has a net asset value of 3.21 billion yuan, ranking 14th in the industry [3] - The company’s net profit margin is -10.73%, ranking 38th in the industry [3] - The return on equity (ROE) stands at -4.6%, ranking 39th in the industry [3] Recent Trading Activity - On October 16, 2025, the main funds experienced a net outflow of 1.4728 million yuan, accounting for 2.77% of the total transaction amount [1] - Retail investors saw a net outflow of 52,100 yuan, representing 0.1% of the total transaction amount [1] - Over the past five days, the stock has seen fluctuations in net inflows and outflows from different investor categories, indicating varying levels of market interest [2]

Core Viewpoint - The company is experiencing a decline in revenue and performance due to tightening medical policies, anti-corruption measures, and a decrease in inpatient numbers, while outpatient services are growing [2]. Group 1: Company Performance - As of October 15, 2025, the company's stock closed at 4.97 yuan, with a 0.61% increase and a trading volume of 12.12 million shares, amounting to a transaction value of 60.07 million yuan [1]. - The company reported a main business revenue growth rate of -17.24%, with a significant drop in industry ranking by 55.56%, indicating weakened competitiveness [2]. - The company's liquidity ratio stands at 28.16%, placing it in the bottom 3.7% of the industry, reflecting weak competitive strength [2]. Group 2: Strategic Response - The company plans to enhance its competitive advantage through a differentiated strategy, focusing on service value addition and business structure adjustment [2]. - Future initiatives include expanding into aesthetic medicine, rehabilitation, women's and children's health, health management, traditional Chinese medicine, assisted reproduction, mental health, and specialized services [2]. - The company aims to optimize resource allocation, merge departments, strengthen cost control, and improve financial management of pharmaceuticals and consumables [2]. Group 3: Market Activity - On October 15, the net inflow of main funds was 228,300 yuan, accounting for 0.38% of the total transaction value [3]. - Retail investors experienced a net outflow of 1,838,100 yuan, representing 3.06% of the total transaction value [3].

Core Insights - The company aims to develop a differentiated strategy to build competitive advantages and enhance service value [2] Business Strategy - The company plans to adjust its business structure by actively laying out in various sectors including medical aesthetics, rehabilitation, women's and children's health, health management, traditional Chinese medicine, assisted reproduction, mental health, and special services [2] - The company intends to expand its services by opening elderly care facilities and specialized departments such as proton therapy to meet market demand [2] Operational Efficiency - The company will focus on resource integration and departmental optimization, strengthening cost control and management of pharmaceutical supplies, while optimizing financial costs [2]

Core Insights - The establishment of the Fangchenggang International Medical Open Experimental Zone is aimed at promoting international medical innovation cooperation and building a global health community, as initiated by President Xi Jinping in 2019 [1][2] - The zone has made significant progress in international medical exchanges and cooperation, signing memorandums with foreign parks and hosting numerous international forums [2][3] - The China-ASEAN Regional Pharmaceutical Trading Platform has been launched, facilitating cross-border transactions and supporting Chinese pharmaceutical companies in entering ASEAN markets [4][5] Group 1: International Cooperation and Development - The Fangchenggang International Medical Open Experimental Zone has signed cooperation memorandums with three foreign parks, including Uzbekistan and Pakistan, and has established partnerships for traditional medicine and medical device trade [2] - The zone has hosted over 10 international medical forums, with participation from over 630 officials and experts from 39 countries, resulting in the release of key documents like the "Fangchenggang Declaration" [3] - The zone has actively engaged in international exchanges, sending 209 delegations to 28 countries and collaborating with 11 international sister cities [3] Group 2: Platform and Infrastructure Development - The China-ASEAN Regional Pharmaceutical Trading Platform has been officially launched, featuring 781 types of drugs and 1,652 categories of medical supplies, with participation from 114 Chinese pharmaceutical companies [4] - The platform aims to provide a comprehensive process for cross-border transactions, enhancing the efficiency and safety of medical product exchanges [4] - The establishment of various major platforms, including a national food safety and nutrition innovation platform and a key laboratory for bioactive molecules, has been prioritized to accelerate innovation [5] Group 3: Investment and Financial Initiatives - A QFLP fund with a total scale of 500 million yuan has been established in collaboration with Singapore's UOB, with 200 million yuan already contributed [5] - The Fangchenggang International Medical Open Experimental Zone has seen a significant increase in registered medical device products, from 3 in 2019 to 165 currently, with 37 medical device companies operating in the area [5]